Publications

Export 8 results:
Author Title [ Type(Asc)] Year
Filters: Author is Macqueen, Glenda M  [Clear All Filters]
Journal Article
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
Lopez JPablo, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C et al..  2017.  MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.
Ju C, Fiori LM, Belzeaux R, Théroux J-F, Chen GGang, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P et al..  2019.  Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.
Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AArias, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B et al..  2014.  The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data.. Brain Imaging Behav. 8(2):153-82.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR et al..  2016.  Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, McAndrews MPat, Blier P, Evans K, Foster JA, Frey BN et al..  2017.  The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.
Kennedy SH, Lam RW, McIntyre RS, S Tourjman V, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, Macqueen GM et al..  2016.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.
Yrondi A, Fiori LM, Frey BN, Lam RW, Macqueen GM, Milev R, Müller DJ, Foster JA, Kennedy SH, Turecki G.  2019.  Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.